Movement and extrapyramidal disorders associated with interferon use in HIV/hepatitis C coinfection.
Brito
Maximo O
MO
Doyle
Timothy
T
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D002819:Chorea / Q000139:chemically induced; D020820:Dyskinesias / Q000209:etiology*; D015658:HIV Infections / Q000188:drug therapy*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D009207:Myoclonus / Q000139:chemically induced; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011595:Psychomotor Agitation / Q000209:etiology; D011994:Recombinant Proteins
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a